Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
FDA approves once-daily Qtern (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes
-
ZS-9 (sodium zirconium cyclosilicate) receives positive CHMP opinion for the treatment of hyperkalaemia
-
AstraZeneca enters agreement with TerSera Therapeutics for Zoladex in the US and Canada
-
Updated durvalumab monotherapy data confirm results in urothelial bladder cancer
-
Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer
-
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasis
-
Full-Year and Q4 2016 Results
-
Symbicort granted paediatric exclusivity in the US
-
AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities
-
AstraZeneca and Lilly to develop second potentially disease-modifying treatment for Alzheimer’s disease
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
